We represented AbbVie in a patent impeachment action brought by Samsung Bioepis in relation to Samsung Bioepis’ biosimilar to AbbVIe’s blockbuster drug HUMIRA.  This case was settled during the discovery phase as part of a global settlement between AbbVie and Samsung Bioepis.